Managing adverse drug reactions (ADRs) remains a significant hurdle despite the high efficacy of standard anti-tuberculosis treatments. The majority of ADRs were classified as clinical (53%), predominantly occurring early in treatment (82.5%) and characterized as mild to moderate (88.7%), mainly falling under "metabolic and nutritional disorders." Interestingly, while there were no significant differences in ADR types, severity, or causality between early and late occurrences, the early group showed a higher incidence of metabolic and gastrointestinal disorders, whereas skin-related issues were more prevalent in the late stage of treatment. These findings underscore the frequent occurrence of ADRs throughout TB treatment, emphasizing the importance of vigilant monitoring and timely intervention to enhance patient safety and treatment adherence.
Keywords: Adverse drug reactions, Anti-TB Treatment, Directly observed pulmonary tuberculosis, Treatment short-course, Tuberculosis.
